Aortic Valve SclerosisNCT06965218
Relation Between Aortic Sclerosis &Severity of Coronary Heart Disease.
An observational study of Aortic Valve Sclerosis, run by Sohag University at 1 site in Egypt.
Trial summary
the goal of the study to identify the relation between aortic valve sclerosis and severity of coronary heart disease by performing transthoracic echo Doppler study for severity of aortic valve sclerosis in patient will undergo coronary angiography with calculation of syntax score as a tool for severity of coronary… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Aortic Valve Sclerosis
- What is being tested?
- Trans thoracic echo doppler
- How many people
- 100 participants
- Where
- 1 siteEgypt
- Study dates
- 1 May 2025to May 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: 100a patients from both sex who are diagnosed to be aortic valve sclerosis and will undergo coronary angiography in Sohag university hospital
Who may be able to join
- Aortic sclerosis diagnosed by trans thoracic echo doppler
Who cannot join
- patients who known to be Rumatic heart disease or congenital aortic valve disease.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site
Sohag faculty of medicine
Sohag
Mohamed Ali shaker, MD, 0021003474075, mohamed_ali_post@med.sohag.edu.eg
About this study
Official title: Relation Between Aortic Valve Sclerosis and Severity of Coronary Heart Disease Assessed by Syntax Score in Sohag University Hospital
the goal of the study to identify the relation between aortic valve sclerosis and severity of coronary heart disease by performing transthoracic echo Doppler study for severity of aortic valve sclerosis in patient will undergo coronary angiography with calculation of syntax score as a tool for severity of coronary heart disease.
- Conditions
- Aortic Valve Sclerosis
- Being tested
- Trans thoracic echo doppler
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Trans thoracic echo dopplerDiagnostic test
Aortic valve sclerosis severity study be transthoracic echo doppler
What is being measured
The primary outcome is the main question the study is designed to answer.
relation between Aortic valve sclerosis and severity of coronary heart disease
significant relation between severity of aortic valve sclerosis assessed by trans thoracic echo doppler quantified by Chandra et al on a scale of 0 to 3.
0 (no involvement).
- mild (minor involvement of one leaflet)
- moderate (minor involvement of two leaflets or extensive involvement of one leaflet.
- severe (extensive involvement of two leaflets or involvement of all three leaflets).
And severity of coronary heart disease in patients already underwent or planned to perform coronary angiography quantified by syntax score considering score above 20 as severe coronary heart disease.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 May 2025
- Study start1 May 2025 (estimated)
- Primary completionNov 2025 (estimated)
- Study completionMay 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Aortic Valve SclerosisStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case crossover
- Time perspective
- Cross-sectional
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Aly Mohamed, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06965218
- Sponsor's protocol ID
- Soh-Med-25-4___1MD
- Status last verified
- May 2025
- First submitted
- 24 Apr 2025
- Last updated
- 11 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Relation Between Aortic Valve Sclerosis and Severity of Coronary Heart Disease Assessed by Syntax Score in Sohag University Hospital
- ClinicalTrials.gov ID
- NCT06965218
- Acronym / sponsor ID
- Soh-Med-25-4___1MD
- Conditions
- Aortic Valve Sclerosis
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 May 2025 (estimated)
- Primary completion
- Nov 2025 (estimated)
- Study completion
- May 2026 (estimated)
- First posted
- 11 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
the goal of the study to identify the relation between aortic valve sclerosis and severity of coronary heart disease by performing transthoracic echo Doppler study for severity of aortic valve sclerosis in patient will undergo coronary angiography with calculation of syntax score as a tool for severity of coronary heart disease.
Study design
- Observational model
- Case crossover
- Time perspective
- Cross-sectional
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- 100a patients from both sex who are diagnosed to be aortic valve sclerosis and will undergo coronary angiography in Sohag university hospital
Key inclusion criteria (1 listed)
- Aortic sclerosis diagnosed by trans thoracic echo doppler
Key exclusion criteria (1 listed)
- patients who known to be Rumatic heart disease or congenital aortic valve disease.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Trans thoracic echo dopplerAortic valve sclerosis severity study be transthoracic echo doppler | Diagnostic test | – |
Primary outcome
relation between Aortic valve sclerosis and severity of coronary heart disease
Time frame: 6 months
significant relation between severity of aortic valve sclerosis assessed by trans thoracic echo doppler quantified by Chandra et al on a scale of 0 to 3. 0 (no involvement). 1. mild (minor involvement of one leaflet) 2. moderate (minor involvement of two leaflets or extensive involvement of one leaflet. 3. severe (extensive involvement of two leaflets or involvement of all three leaflets). And severity of coronary heart disease in patients already underwent or planned to perform coronary angiography quantified by syntax score considering score above 20 as severe coronary heart disease.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 May 2025.
Related trials for Aortic Valve Sclerosis
Enrolling by invitation
Parent and Infant Inter(X)Action Intervention (PIXI)
Fragile X Syndrome, Angelman Syndrome
Active, not recruitingObservational study
Early Check: Expanded Screening in Newborns
Spinal Muscular Atrophy, Fragile X Syndrome
RecruitingObservational study
GROWing Up With Rare GENEtic Syndromes
Prader-Willi Syndrome, PWS-like Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Aortic Valve Sclerosis, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 11 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mohamed Ali shaker, MD (0021003474075, mohamed_ali_post@med.sohag.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
relation between Aortic valve sclerosis and severity of coronary heart disease (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 May 2025.